KBC Group NV cut its position in bluebird bio, Inc. (NASDAQ:BLUE) by 27.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,543 shares of the biotechnology company’s stock after selling 4,415 shares during the quarter. KBC Group NV’s holdings in bluebird bio were worth $1,585,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of BLUE. QS Investors LLC grew its stake in bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares in the last quarter. Bank of Montreal Can grew its stake in bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC acquired a new position in bluebird bio during the 2nd quarter worth $184,000. Biondo Investment Advisors LLC acquired a new position in bluebird bio during the 3rd quarter worth $203,000. Finally, SG Americas Securities LLC grew its stake in bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares in the last quarter.

BLUE has been the subject of several analyst reports. Goldman Sachs Group reissued a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research note on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and set a $170.00 price objective (up from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. BMO Capital Markets upped their price objective on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday, October 30th. BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price objective for the company in a research report on Thursday, November 2nd. Finally, SunTrust Banks upped their price objective on bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and a consensus price target of $147.90.

In other news, insider Jeffrey T. Walsh sold 35,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the completion of the transaction, the insider now directly owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey T. Walsh sold 4,900 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $129.94, for a total value of $636,706.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 99,550 shares of company stock valued at $14,413,376. 3.90% of the stock is owned by company insiders.

Shares of bluebird bio, Inc. (BLUE) opened at $201.80 on Tuesday. bluebird bio, Inc. has a one year low of $60.95 and a one year high of $222.03.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue was up 397.4% on a year-over-year basis. During the same period in the prior year, the company earned ($2.07) earnings per share. research analysts forecast that bluebird bio, Inc. will post -6.68 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) Shares Sold by KBC Group NV” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/bluebird-bio-inc-blue-shares-sold-by-kbc-group-nv/1758729.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.